Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 25, 2017

Study Completion Date

August 25, 2017

Conditions
Respiratory Distress Syndrome in Premature InfantBronchopulmonary Dysplasia
Interventions
DRUG

Half normal saline

2 ml/kg

DRUG

Low Dose rhCC10

1.5 mg/kg study drug (rhCC10)

DRUG

High dose rhCC10

5 mg/kg in 2 ml/kg

Trial Locations (3)

02111

Tufts Medical Center, Boston

02115

Brigham and Women's Hospital, Boston

01199

Baystate Medical Center, Springfield

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Therabron Therapeutics, Inc.

INDUSTRY

collaborator

Baystate Medical Center

OTHER

collaborator

Poznan University of Medical Sciences

OTHER

collaborator

SP ZOZ Szpital Uniwersytecki w Krakowie Oddizat Neonatologii

UNKNOWN

collaborator

Instytut Centrum Zdrowia Matki Polki Klinika Neonatologii

UNKNOWN

lead

Tufts Medical Center

OTHER

NCT01941745 - Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome | Biotech Hunter | Biotech Hunter